Impact Factor
2.59
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
0.84
771 total citations
h5-index
28
h5 depth signal
Cited share
28.3%
264 of 934
Total citations
771
Citation footprint
Metric signal
0.62
External metric anchor
Self-citation
1.8%
14 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
1,417
Italy
838
China
723
France
553
United Kingdom
496
Citing Fields of Research
Lymphomas
3,529
Hematology
862
Immunology
663
Oncology
329
Palliative Care
176
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
5,781
Articles tracked across the journal lifetime
Indexed publication set
934
264 cited publications
Last 12 months
131
10.9 publications/month
Open access share
41.2%
54 OA publications in the last year
Leading citing country
United States
1,417 citing publications
Leading citing field
Lymphomas
3,529 citing publications
Latest tracked publication
20 October 2026
10 recent records available
Coverage & Indexing History
v1n1, 1983-
v1n1, 1983-
Active Coverage
Research Focus & Classification
Indexed Subjects
Lymphomas
Broad Categories
Hematology
Neoplasms
Lymphomas
MeSH Descriptors
Hematology
Medical Oncology
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
02
DOI 10.1002/hon.70278
Open DOI
Teclistamab Induced a Profound Hematologic Response in Light Chain Deposition Disease With Probable Cardiac Involvement
We report the first case of using teclistamab, a BCMA × CD3 bispecific antibody, in a 63‐year‐old male with κ ‐light chain deposition disease (LCDD) involving the kidneys and probably the heart. The patient initially responded to daratum...
03
DOI 10.1002/hon.70268
Open DOI
Non‐Relapse Mortality With Bispecific Antibodies in Hematologic Malignancies: A Dual Systematic Review and Pharmacovigilance Analysis
Bispecific antibodies (BsAbs) redirect T‐cells to tumor antigens in an MHC‐independent manner. These universally available, off‐the‐shelf products have demonstrated unprecedented efficacy in heavily pretreated patients with relapsed/refr...
04
DOI 10.1002/hon.70277
Open DOI
NFS1 as a Metabolic Vulnerability in Acute Myeloid Leukemia Through Iron Dysregulation and STAT1/IFIT2‐Associated Signaling
Acute myeloid leukemia (AML) is a metabolically heterogeneous malignancy with poor outcomes and limited durable therapeutic options. We investigated NFS1, a key enzyme involved in iron‐sulfur cluster biogenesis, as a potential metabolic ...
05
DOI 10.1002/hon.70273
Open DOI
Clinical Characteristics of Coexistent Chronic Myeloid Leukemia and BCR::ABL1 Negative Myeloproliferative Neoplasms: A Retrospective Study
Coexistent chronic myeloid leukemia (CML) and BCR::ABL1 ‐negative myeloproliferative neoplasms (MPN) are rare. We aimed to evaluate their clinical and therapeutic profiles. We retrospectively evaluated 36 institutional patients with coex...
06
DOI 10.1002/hon.70253
Open DOI
Real‐World Survival Outcomes of Venetoclax Combination Therapies in Acute Myeloid Leukemia: Impact of Minimal Residual Disease Status and Antifungal Prophylaxis
In recent years the addition of the oral BCL2 inhibitor venetoclax to hypomethylating agents (HMAs) has emerged as the standard‐of‐care for patients with acute myeloid leukemia (AML) who are not fit for intensive chemotherapy, significan...
07
08
DOI 10.1002/hon.70270
Open DOI
Accelerated Glofitamab as Urgent Bridging to CAR T‐Cell Therapy in High‐Risk Relapsed/Refractory Large B‐Cell Lymphoma
Conventional glofitamab step‐up dosing reaches the 30‐mg target dose approximately 3 weeks after obinutuzumab. This interval may be difficult to accommodate in patients with relapsed or refractory large B‐cell lymphoma (R/R LBCL) who req...
09
DOI 10.1002/hon.70266
Open DOI
Peripheral CD4 + T‐Cell Reserve as a Potential Biomarker of CD20 × CD3 Bispecific Antibody Outcomes and BTK Inhibitor–Associated Immune Modulation in B‐Cell Lymphoma
Bispecific antibodies (BsAbs) targeting CD20 × CD3 have achieved remarkable efficacy in relapsed or refractory (R/R) B‐cell lymphoma, yet clinical responses remain heterogeneous and predictive biomarkers are lacking. We retrospectively e...
10
Bibliographical & Catalog Notes
Title from cover.
Print issues ceased with v. 28, no. 4 (2010)
Also issued online.
Vol. 8, no. 1 (JAN-FEB 1990)19900918 Notice published Printed on acid-free paper